Reuters logo
3 个月前
BRIEF-Minerva provides update on phase 3 design and development strategy for MIN-101
2017年5月15日 / 中午12点25分 / 3 个月前

BRIEF-Minerva provides update on phase 3 design and development strategy for MIN-101

May 15 (Reuters) - Minerva Neurosciences Inc

* Minerva provides update on phase 3 design and development strategy for MIN-101

* Minerva Neurosciences Inc - in phase 4 development, company plans to conduct additional trials to expand profile of MIN-101

* Minerva Neurosciences Inc -co's next step is planned initiation of a pivotal phase 3 trial with MIN-101 in second half of 2017

* Minerva Neurosciences - plans for its phase 3 and phase 4 clinical development of MIN-101, a drug targeting negative symptoms in schizophrenia patients

* Minerva Neurosciences Inc says may conduct a trial in adolescents at high risk for schizophrenia who during prodromal phase manifest negative symptoms

* Minerva Neurosciences- plans to assess indications as expansion options for MIN-101 in development program beyond planned phase 3 study in schizophrenia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below